Focus on complex multivessel coronary artery disease management with an emphasis on severely calcified lesions and the integration of intracoronary imaging and physiology. This session prepares clinicians to anticipate and manage complications during PCI, enhancing competence in treating challenging coronary anatomies through case-based decision-making.

This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...

Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.

Explore a series of challenging cases in coronary bifurcation interventions, highlighting complex decision-making scenarios, pharmaco-invasive strategies guided by IVUS, and tailored techniques for reintervention. Emphasis is placed on imaging-guided PCI and simplifying complex double bifurcation and long lesion treatments to optimize patient outcomes.

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.